SEC 13F Intelligence

Managers / Q1 2024 · view latest →

Lion Point Capital, LP

CIK 0001643354 · 375 PARK AVE, SUITE 2609, NEW YORK, NY, 10152 · 212-356-6200

Reported Value
$179M
Q1 2024
Positions
32
Filings on Record
31
2019–present window
Filed
May 15, 2024
original filing

Summary

Lion Point Capital, LP reported $179M in U.S.-listed holdings across 32 positions for Q1 2024.

Its largest position, Marinus Pharmaceuticals, represents 10.7% of the portfolio.

Compared with Q4 2023, the fund opened 7 new positions and exited 5.

Portfolio Metrics

Turnover
+18.0%
vs prior filed quarter
Top-10 Concentration
+24.5%
share of reported value
Largest Position
+10.7%
Marinus Pharmaceuticals
New / Exited
7 / 5
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $636MQ4 ’18Q1 ’19: $1.1BQ2 ’19: $1.0BQ3 ’19: $897MQ4 ’19: $1.1BQ4 ’19Q1 ’20: $379MQ2 ’20: $412MQ3 ’20: $456MQ4 ’20: $519MQ4 ’20Q1 ’21: $550MQ2 ’21: $579MQ3 ’21: $533MQ4 ’21: $373MQ4 ’21Q1 ’22: $431MQ2 ’22: $878MQ3 ’22: $454MQ4 ’22: $703MQ4 ’22Q1 ’23: $243MQ2 ’23: $221MQ3 ’23: $224MQ4 ’23: $200MQ4 ’23Q1 ’24: $179MQ2 ’24: $55MQ3 ’24: $45MQ4 ’24: $19MQ4 ’24Q1 ’25: $16MQ2 ’25: $15MQ3 ’25: $18MQ4 ’25: $19MQ4 ’25Q1 ’26: $17Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 64.5%ETP: 31.7%Other: 3.4%US DOMESTIC: 0.4%
  • Common Stock · 64.5% · $115M
  • ETP · 31.7% · $57M
  • Other · 3.4% · $6M
  • US DOMESTIC · 0.4% · $629,500

Quarter-over-Quarter Changes full breakdown →

vs Q4 2023 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
SPDR SER TRNEW+50.0K50.0K+$5M$5M
GONGERON CORPNEW+600.0K600.0K+$2M$2M
NBIXNEUROCRINE BIOSCIENCES INCNEW+7.5K7.5K+$1M$1M
JSPRJASPER THERAPEUTICS INCNEW+32.0K32.0K+$939,520$939,520
MLYSMINERALYS THERAPEUTICS INCNEW+60.0K60.0K+$774,600$774,600
RGNXREGENXBIO INCNEW+32.5K32.5K+$684,775$684,775
SPRUCE BIOSCIENCES INCNEW+75.0K75.0K+$58,943$58,943
MIRMMIRUM PHARMACEUTICALS INCADDED+31.5K45.0K+$731,880$1M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2024

26 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1MARINUS PHARMACEUTICALS INCCOM NEW10.71%$19M2.12M
2ARDXARDELYX INChistory →COM4.27%$8M1.05M
3MISTMILESTONE PHARMACEUTICALS INhistory →COM2.30%$4M2.30M
4KINIKSA PHARMACEUTICALS LTDCOM CL A1.44%$3M130.7K
5GONGERON CORPhistory →COM1.11%$2M600.0K
6IM8NINSMED INChistory →COM PAR $.011.07%$2M70.3K
7FRXFENNEC PHARMACEUTICALS INChistory →COM1.06%$2M170.0K
80LSBURGERFI INTERNATIONAL INCCOM · *W EXP 12/16/2020.93%$2M4.83M
9SNDXSYNDAX PHARMACEUTICALS INCCOM0.86%$2M65.0K
10AVADEL PHARMACEUTICALS PLCSPONSORED ADR0.78%$1M82.5K
11TVTXTRAVERE THERAPEUTICS INCNOTE 2.250% 3/0 · COM0.69%$1M1.08M
12BLUEBIRD BIO INCCOM0.61%$1M848.3K
13NBIXNEUROCRINE BIOSCIENCES INCCOM0.58%$1M7.5K
14JSPRJASPER THERAPEUTICS INCCOM NEW0.53%$939,52032.0K
15ENPHYS ACQUISITION CORPCL A ORD SHS0.47%$845,31378.1K
16MLYSMINERALYS THERAPEUTICS INCCOM0.43%$774,60060.0K
17HUMAHUMACYTE INCCOM0.41%$730,850235.0K
18RGNXREGENXBIO INCCOM0.38%$684,77532.5K
19REPLREPLIMUNE GROUP INCCOM0.19%$347,22542.5K
20MCRB1EURSERES THERAPEUTICS INCCOM0.15%$263,783340.8K
21LUMOS PHARMA INCCOM0.14%$256,03990.8K
22BATLBATTALION OIL CORPORATIONCOM0.06%$112,78119.9K
23SPRUCE BIOSCIENCES INCCOM0.03%$58,94375.0K
24MSFTMICROSOFT CORPCOM0.02%$42,072100
25GOOGALPHABET INCCAP STK CL C0.01%$15,226100
26SMTCSEMTECH CORPCOM0.00%$38514

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$17M35May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$19M39Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$18M27Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$15M19Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$16M21May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$19M19Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$45M25Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$55M27Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$179M32May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$200M30Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$224M31Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$221M30Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$243M31May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$703M32Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$454M41Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$878M40Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$431M35May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$373M33Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$533M38Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$579M34Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$550M30May 19, 2021RESTATEMENTchanges · EDGAR ↗
Q4 2020$519M24Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$456M24Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$412M24Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$379M25May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$1.1B26Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$897M26Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$1.0B24Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$1.1B24May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$636M35Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.